

November 24, 2014



## XOMA to Present at the Piper Jaffray Healthcare Conference

BERKELEY, Calif., Nov. 24, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today John Varian, the Company's Chief Executive Officer, is scheduled to present at the 26<sup>th</sup> Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014, at 9:30 a.m. ET.

A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA's website at <http://investors.xoma.com/events.cfm>. An archived version of the webcast will be available via replay for 60 days following the presentation.

### About XOMA Corporation

XOMA's innovative product candidates are the result of the Company's expertise in developing allosteric modulating monoclonal antibodies, which has created opportunities to develop new classes of therapeutic antibodies with the potential to treat a wide range of human diseases. XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with SERVIER through a global Phase 3 program for Behçet's disease uveitis, non-infectious uveitis, and pyoderma gangrenosum and ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA's scientific research also produced the XMet program, which consists of three classes of antibodies, including XOMA 358, an allosteric monoclonal antibody that reduces both the binding of insulin to its receptor and downstream insulin signaling, that could have a major effect on the treatment of abnormal metabolic states.

More detailed information can be found at [www.xoma.com](http://www.xoma.com).

CONTACT: Company and Investor Contacts:  
Ashleigh Barreto  
510-204-7482  
barreto@xoma.com

Juliane Snowden  
The Oratorium Group, LLC  
jsnowden@oratoriumgroup.com

Source: XOMA Corporation